СОВМЕСТНОЕ ЭКСПЕРТНОЕ ЗАКЛЮЧЕНИЕ АМЕРИКАНСКОГО ОБЩЕСТВА СЕРДЕЧНОГО РИТМА (HRS) ПО УДАЛЁННОЙ ТЕЛЕМЕТРИИ И МОНИТОРИНГУ СЕРДЕЧНО-СОСУДИСТЫХ ИМПЛАНТИРУЕМЫХ ЭЛЕКТРОННЫХ УСТРОЙСТВ

1. Wilkoff B.L., Auricchio A., Brugada J., et al. HRS/EHRA Expert Consensus on the Monitoring of Cardiovascular Implantable Electronic Devices (CIEDs): descrip-tion of techniques, indications, personnel, frequency and ethical considerations: developed in partnership with the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA); and in collaboration with the American College of Cardiology (ACC), the American Heart Association (AHA), the European Society of Cardiology (ESC), the Heart Failure Association of ESC (HFA), and the Heart Failure Society of America (HFSA). Endorsed by the Heart Rhythm Society, the European Heart Rhythm Association (a registered branch of the ESC), the American College of Cardiology, the American Heart Association. Heart Rhythm 2008; 5: 907-925

2. Al-Khatib S.M., Mi X., Wilkoff B.L., Qualls L.G., Frazier-Mills C., Setoguchi S., Hess P.L., Curtis L.H. Follow-up of patients with new cardiovascular implantable electronic devices: are experts’ recommendations implemented in routine clinical practice? Circ Arrhythm Electrophysiol 2013; 6: 108-116

3. Halimi F., Clementy J., Attuel P., Dessenne X., Amara W.; OEDIPE Trial Investigators. Optimized post-operative surveillance of permanent pacemakers by home monitoring: the OEDIPE trial. Europace 2008; 10: 1392-1399.

4. Dubner S., Auricchio A., Steinberg J.S., et al. ISHNE/ EHRA expert consensus on remote monitoring of cardiovascular implantable electronic devices (CIEDs). Ann Noninvasive Electrocardiol 2012; 17: 36-56.

5. Burri H. Remote follow-up and continuous remote monitoring, distinguished. Europace 2013; 15: i14-i16.

6. Varma N., Pavri B.B., Stambler B., Michalski J.; TRUST Investigators. Same-day discovery of implantable cardioverter defibrillator dysfunction in the TRUST remote monitoring trial: influence of contrasting messaging systems. Europace 2013; 15: 697-703.

7. Varma N., Stambler B., Chun S. Detection of atrial fibrillation by implanted devices with wireless data transmission capability. Pacing Clin Electrophysiol 2005; 28: S133-S136.

8. Jacobs A.K., Anderson J.L., Halperin J.L. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: 1373-1384.

9. Crossley G.H., Chen J., Choucair W., Cohen T.J., Gohn D.C., Johnson W.B., Kennedy E.E., Mongeon L.R., Serwer G.A., Qiao H., Wilkoff B.L. Clinical benefits of remote versus transtelephonic monitoring of implanted pacemakers. J Am Coll Cardiol 2009; 54: 2012-2019.

10. Schoenfeld M.H., Compton S.J., Mead R.H., Weiss D.N., Sherfesee L., Englund J., Mongeon L.R. Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. Pacing Clin Electrophysiol 2004; 27: 757-763.

11. Al-Khatib S.M., Piccini J.P., Knight D., Stewart M., Clapp-Channing N., Sanders G.D. Remote monitoring of implantable cardioverter defibrillators versus quarterly device interrogations in clinic: results from a randomized pilot clinical trial. J Cardiovasc Electrophysiol 2010; 21: 545-550.

12. Cronin E.M., Ching E.A., Varma N., Martin D.O., Wilkoff B.L., Lindsay B.D. Remote monitoring of cardiovascular devices: a time and activity analysis. Heart Rhythm 2012; 9: 1947-1951.

13. Theuns D.A., Res J.C., Jordaens L.J. Home monitoring in ICD therapy: future perspectives. Europace 2003; 5: 139-142.

14. Joseph G.K., Wilkoff B.L., Dresing T., Burkhardt J., Khaykin Y. Remote inter-rogation and monitoring of implantable cardioverter defibrillators. J Interv Card Electrophysiol 2004; 11: 161-166.

15. Varma N., Epstein A.E., Irimpen A., Schweikert R., Love C.; TRUST Investigators. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T Safely Reduces Routine Office Device Follow-up (TRUST) trial. Circulation 2010; 122: 325-332.

16. Varma N., Michalski J., Stambler B., Pavri B.B.; TRUST Investigators. Superiority of automatic remote monitoring compared with in-person evaluation for scheduled ICD follow-up in the TRUST trial-testing execution of the recommendations. Eur Heart J 2014; 35: 1345-1352.

17. Ricci R.P., Morichelli L., D’Onofrio A., Calô L., Vaccari D., Zanotto G., Curnis A., Buja G., Rovai N., Gargaro A. Effectiveness of remote monitoring of CIEDs in detection and treatment of clinical and device-related cardiovascular events in daily practice: the HomeGuide Registry. Europace 2013; 15: 970-977.

18. Ricci R.P., Morichelli L., D’Onofrio A., Calo L., Vaccari D., Zanotto G., Curnis A., Buja G., Rovai N., Gargaro A. Manpower and outpatient clinic workload for remote monitoring of patients with cardiac implantable electronic devices: data from the HomeGuide Registry. J Cardiovasc Electrophysiol 2014; 25: 1216-1223.

19. Hindricks G., Elsner C., Piorkowski C., Taborsky M., Geller J.C., Schumacher B., Bytesnik J., Kottkamp H. Quarterly vs. yearly clinical follow-up of remotely monitored recipients of prophylactic implantable cardioverter-defibrillators: results of the REFORM trial. Eur Heart J 2014; 35: 98-105.

20. Boriani G., Da Costa A., Ricci R.P., et al. The MOnitoring Resynchronization dEvices and CARdiac patiEnts (MORE-CARE) randomized controlled trial: phase 1 results on dynamics of early intervention with remote monitoring. J Med Internet Res 2013; 15: e167.

21. Crossley G., Boyle A., Vitense H., Chang Y., Mead R.H. The CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial: the value of wireless remote monitoring with automatic clinician alerts. J Am Coll Cardiol 2011; 57: 1181-1189.

22. Varma N. Rationale and design of a prospective study of the efficacy of a remote monitoring system used in implantable cardioverter defibrillator follow-up: the Lumos-T Reduces Routine Office Device Follow-Up Study (TRUST) study. Am Heart J 2007; 154: 1029-1034.

23. Guedon-Moreau L., Lacroix D., Sadoul N., Clementy J., Kouakam C., Hermida J.S., Aliot E., Boursier M., Bizeau O., Kacet S. A randomized study of remote follow-up of implantable cardioverter defibrillators: safety and efficacy report of the ECOST trial. Eur Heart J 2012; 34: 605-614.

24. Lazarus A. Remote, wireless, ambulatory monitoring of implantable pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy systems: analysis of a worldwide database. Pacing Clin Electrophysiol 2007; 30: S2-S12.

25. Mabo P., Victor F., Bazin P., Ahres S., Babuty D., Da Costa A., Binet D., Daubert J.C.; COMPAS Trial Investigators. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur Heart J 2012; 33: 1105-1111.

26. Varma N., Michalski J., Epstein A.E., Schweikert R. Automatic remote monitoring of implantable cardioverter-defibrillator lead and generator performance: the Lumos-T Safely RedUceS RouTine Office Device Follow-up (TRUST) Trial. Circ Arrhythm Electrophysiol 2010; 3: 428-436.

27. Landolina M., Perego G.B., Lunati M., Curnis A., Guenzati G., Vicentini A., Parati G., Borghi G., Zanaboni P., Valsecchi S., Marzegalli M. Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. Circulation 2012; 125: 2985-2992.

28. Calô L., Gargaro A., De Ruvo E., Palozzi G., Sciarra L., Rebecchi M., Guarracini F., Fagagnini A., Piroli E., Lioy E., Chirico A. Economic impact of remote monitoring on ordinary follow-up of implantable cardioverter defibrillators as compared with conventional in-hospital visits: a singlecenter prospective and randomized study. J Interv Card Electrophysiol 2013; 37: 69-78.

29. Hindricks G., Taborsky M., Glikson M., et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 2014; 384: 583-590.

30. Saxon L.A., Hayes D.L., Gilliam F.R., Heidenreich P.A., Day J., Seth M., Meyer T.E., Jones P.W., Boehmer J.P. Longterm outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation 2010; 122: 2359-2367.

31. Varma N.P.J., Snell J., Fischer A., Dalal N., Mittal S. The relationship between level of adherence to automatic wireless remote monitoring and survival in pacemaker and defibrillator patients. J Am Coll Cardiol. In press. Available at: http://dx.doi.org/10.1016/j.jacc.2015.04.033.

32. Fauchier L., Sadoul N., Kouakam C., Briand F., Chauvin M., Babuty D., Clementy J. Potential cost savings by telemedicine-assisted long-term care of implantable cardioverter defibrillator recipients. Pacing Clin Electrophysiol 2005; 28: S255-S259.

33. Raatikainen M.J., Uusimaa P., van Ginneken M.M., Janssen J.P., Linnaluoto M. Remote monitoring of implantable cardioverter defibrillator patients: a safe, time-saving, and cost-effective means for follow-up. Europace 2008; 10: 1145-1151.

34. Marzegalli M., Lunati M., Landolina M., et al. Remote monitoring of CRT-ICD: the multicenter Italian CareLink evaluation-ease of use, acceptance, and organizational implications. Pacing Clin Electrophysiol 2008; 31: 1259-1264.

35. Ricci R.P., Morichelli L., Quarta L., Sassi A., Porfili A., Laudadio M.T., Gargaro A., Santini M. Long-term patient acceptance of and satisfaction with implanted device remote monitoring. Europace 2010; 12: 674-679.

36. Petersen H.H., Larsen M.C., Nielsen O.W., Kensing F., Svendsen J.H. Patient satisfaction and suggestions for improvement of remote ICD monitoring. J Interv Card Electrophysiol 2012; 34: 317-324.

37. Morichelli L., Porfili A., Quarta L., Sassi A., Ricci R.P. Implantable cardioverter defibrillator remote monitoring is well accepted and easy to use during long-term follow-up. J Interv Card Electrophysiol 2014; 41: 203-209.

38. Guédon-Moreau L., Lacroix D., Sadoul N., Clémenty J., Kouakam C., Hermida J.S., Aliot E., Kacet S.; ECOST Investigators. Costs of remote monitoring vs. ambulatory follow-ups of implanted cardioverter defibrillators in the randomized ECOST study. Europace 2014; 16: 1181-1188.

39. Zanaboni P., Landolina M., Marzegalli M., Lunati M., Perego G.B., Guenzati G., Curnis A., Valsecchi S., Borghetti F., Borghi G., Masella C. Cost-utility analysis of the EVOLVO study on remote monitoring for heart failure patients with implantable defibrillators: randomized controlled trial. J Med Internet 2013; 15: e106.

40. Burri H., Sticherling C., Wright D., Makino K., Smala A., Tilden D. Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. Europace 2013; 15: 1601-1608.

41. Ricci R.P., Vicentini A., D’Onofrio A., et al. Impact of in-clinic follow-up visits in patients with implantable cardioverter defibrillators: demographic and socio-economic analysis of the TARIFF study population. J Interv Card Electrophysiol 2013; 38: 101-106.

42. de Asmundis C., Ricciardi D., Namdar M., Chierchia G.-B., Sarkozy A., Brugada P. Role of home monitoring in children with implantable cardioverter defibrillators for Brugada syndrome. Europace 2013; 15: i17-i25.

43. Neuzil P., Taborsky M., Holy F., Wallbrueck K. Early automatic remote detection of combined lead insulation defect and ICD damage. Europace 2008; 10: 556-557.

44. Varma N. Remote monitoring for advisories: automatic early detection of silent lead failure. Pacing Clin Electrophysiol 2009; 32: 525-527.

45. Spencker S., Coban N., Koch L., Schirdewan A., Muller D. Potential role of home monitoring to reduce inappropriate shocks in implantable cardioverter-defibrillator patients due to lead failure. Europace 2009; 11: 483-488.

46. Guedon-Moreau L., Kouakam C., Klug D., MarquiÉ C., Brigadeau F., BoulÉ S., Blangy H., Lacroix D., ClÉMenty J., Sadoul N., Kacet S., on behalf of the EtI. Decreased delivery of inappropriate shocks achieved by remote monitoring of ICD: a substudy of the ECOST trial. J Cardiovasc Electrophysiol 2014; 25: 763-770.

47. Ricci R.P., Pignalberi C., Landolina M., et al. Ventricular rate monitoring as a tool to predict and prevent atrial fibrillation-related inappropriate shocks in heart failure patients treated with cardiac resynchronisation therapy defibrillators. Heart 2014; 100: 848-854.

48. Ricci R.P., Morichelli L., Quarta L., Porfili A., Magris B., Giovene L., Torcinaro S., Gargaro A. Effect of daily remote monitoring on pacemaker longevity: a retrospective analysis. Heart Rhythm 2015; 12: 330-337.

49. Medtronic. Clinician Manual Supplement ProtectaTM XT/ProtectaTM Projected service life information related to remote monitoring. EVERA™ XT VR DVBB1D1. Manual No: M945739A001A.

50. Varma N., Johnson M.A. Prevalence of cancelled shock therapy and relationship to shock delivery in recipients of implantable cardioverter-defibrillators assessed by remote monitoring. Pacing Clin Electrophysiol 2009; 32: S42-S46.

51. Ricci R.P., Morichelli L., Santini M. Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation. Europace 2009; 11: 54-61.

52. Ricci R.P., Morichelli L., D’Onofrio A., Calo L., Vaccari D., Zanotto G., Curnis A., Buja G., Rovai N., Gargaro A. Effectiveness of remote monitoring of CIEDs in detection and treatment of clinical and device-related cardiovascular events in daily practice: the HomeGuide Registry. Europace 2013; 15: 970-977.

53. Orlov M.V., Ghali J.K., Araghi-Niknam M., Sherfesee L., Sahr D., Hettrick D.A.; Atrial High Rate Trial Investigators. Asymptomatic atrial fibrillation in pace-maker recipients: incidence, progression, and determinants based on the atrial high rate trial. Pacing Clin Electrophysiol 2007; 30: 404-411.

54. Cheung J.W., Keating R.J., Stein K.M., Markowitz S.M., Iwai S., Shah B.K., Lerman B.B., Mittal S. Newly detected atrial fibrillation following dual chamber pace-maker implantation. J Cardiovasc Electrophysiol 2006; 17: 1323-1328.

55. Bunch T.J., Day J.D., Olshansky B., Stolen K.Q., Mullin C.M.; INTRINSIC RV Study Investigators. Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 2009; 6: 2-8.

56. Botto G.L., Padeletti L., Santini M., et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of throm-boembolic events. J Cardiovasc Electrophysiol 2009; 20: 241-248.

57. Glotzer T.V., Hellkamp A.S., Zimmerman J., et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the atrial diagnostics ancillary study of the MOde Selection Trial (MOST). Circulation 2003; 107: 1614-1619.

58. Capucci A., Santini M., Padeletti L., et al. Monitored atrial fibrillation duration predicts arterial embolic events in patients suffering from bradycardia and atrial fibrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol 2005; 46: 1913-1920.

59. Glotzer T.V., Daoud E.G., Wyse D.G., Singer D.E., Ezekowitz M.D., Hilker C., Miller C., Qi D., Ziegler P.D. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009; 2: 474-480.

60. Shanmugam N., Boerdlein A., Proff J., Ong P., Valencia O., Maier S.K., Bauer W.R., Paul V., Sack S. Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population. Europace 2012; 14: 230-237.

61. Healey J.S., Connolly S.J., Gold M.R., et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120-129.

62. Brambatti M., Connolly S.J., Gold M.R., et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014; 129: 2094-2099.

63. Martin D.T., Bersohn M.M., Waldo A.L., Wathen M.S., Choucair W.K., Lip G.Y.H, Ip J., Holcomb R., Akar J.G., Halperin J.L., on behalf of the IMPACT Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J. In press. Available at: http://eurheartj.oxfordjournals.org/content/ehj/early/2015/04/22/eurheartj.ehv115.full.pdf.

64. January C.T., Wann L.S., Alpert J.S., et al. 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: 2246-2280.

65. Vollmann D., Nägele H., Schauerte P., Wiegand U., Butter C., Zanotto G., Quesada A., Guthmann A., Hill M.R., Lamp B.; EISOS Investigators. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J 2007; 28: 1835-1840.

66. Conraads V.M., Tavazzi L., Santini M., Oliva F., Gerritse B., Yu C.M., Cowie M.R. Sensitivity and positive predictive value of implantable intrathoracic impedance monitoring as a predictor of heart failure hospitalizations: the SENSE-HF trial. Eur Heart J 2011; 32: 2266-2273.

67. Perego G.B., Landolina M., Vergara G., et al. Implantable CRT device diagnostics identify patients with increased risk for heart failure hospitalization. J Interv Card Electrophysiol 2008; 23: 235-242.

68. Small R.S., Wickemeyer W., Germany R., Hoppe B., Andrulli J., Brady P.A., Labeau M., Koehler J., Sarkar S., Hettrick D.A., Tang W.H. Changes in intrathoracic impedance are associated with subsequent risk of hospitalizations for acute decompensated heart failure: clinical utility of implanted device monitoring without a patient alert. J Card Fail 2009; 15: 475-481.

69. Whellan D.J., Ousdigian K.T., Al-Khatib S.M., Pu W., Sarkar S., Porter C.B., Pavri B.B., O’Connor C.M. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. J Am Coll Cardiol 2010; 55: 1803-1810.

70. Catanzariti D., Lunati M., Landolina M., et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol 2009; 32: 363-370.

71. Maines M., Catanzariti D., Cemin C., Vaccarini C., Vergara G. Usefulness of intrathoracic fluids accumulation monitoring with an implantable biventricular defibrillator in reducing hospitalizations in patients with heart failure: a case-control study. J Interv Card Electrophysiol 2007; 19: 201-207.

72. van Veldhuisen D.J., Braunschweig F., Conraads V., et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation 2011; 124: 1719-1726.

73. Hindricks G., Taborsky M., Glikson M., et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet 2014; 384: 583-590.

74. Abraham W.T., Adamson P.B., Bourge R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377: 658-666.

75. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013; 61: e6-e75.

76. Gussak I., Brugada P., Brugada J., Antzelevitch C., Osbakken M., Bjerregaard P. ECG phenomenon of idiopathic and paradoxical short QT intervals. Card Electrophysiol Rev 2002; 6: 49-53.

77. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659-670.

78. de Asmundis C., Ricciardi D., Namdar M., Chierchia G.B., Sarkozy A., Brugada P. Role of home monitoring in children with implantable cardioverter defibrillators for Brugada syndrome. Europace 2013; 15: i17-i25.

79. Schwartz P.J., Spazzolini C., Priori S.G., et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them? Data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010; 122: 1272-1282.

80. Berul C.I., Van Hare G.F., Kertesz N.J., Dubin A.M., Cecchin F., Collins K.K., Cannon B.C., Alexander M.E., Triedman J.K., Walsh E.P., Friedman R.A. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pedia-tric and congenital heart disease patients. J Am Coll Cardiol 2008; 51: 1685-1691.

81. Maron B.J., Spirito P., Shen W.K., et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007; 298: 405-412.

82. Sacher F., Probst V., Bessouet M., et al. Remote implantable cardioverter defibrillator monitoring in a Brugada syndrome population. Europace 2009; 11: 489-494.

83. Hayes D.L., Boehmer J.P., Day J.D., Gilliam F.R. III, Heidenreich P.A., Seth M., Jones P.W., Saxon L.A. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm 2011; 8: 1469-1475.

84. Gilliam F.R., Hayes D.L., Boehmer J.P., Day J., Heidenreich P.A., Seth M., Jones P.W., Stein K.M., Saxon L.A. Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol 2011; 22: 1023-1029.

85. Heart Rhythm Society. Resource-Specifications for HRS-developed Measures. 2015. A HRS-developed physician-level performance measure “In-Person Eval-uation Following Implantation of a Cardiovascular Implantable Electronic Device (CIED)” is available as a tool to measure adherence to in-person follow-up. www.hrsonline.org/hrs/Practice-Guidance/Quality-Outcomes-Reporting/Physician-Quality-Reporting-Systems-PQRS/Resource-Specifications-for-HRS-Measures. Accessed April 8, 2015.

86. Winters S.L., Kusumoto F.M., Miller J.M., Slotwiner D.J. The role of the Heart Rhythm Society in integrating the healthcare enterprise. Heart Rhythm 2007; 4: 122-124.

87. IEEE. 11073-10103-2012-Health informatics-Point-of-care medical device communication Part 10103: Nomenclature-Implantable device, cardiac. http://standards.ieee.org/findstds/standard/11073-10103-2012.html. Accessed April 8, 2015.

88. Integrating the Healthcare Enterprise. Patient Care Device Technical Frame-work. 2014. http://www.ihe.net/Technical_Frameworks/pcd. Accessed April 8, 2015.

89. Heidbuchel H., Hindricks G., Broadhurst P., et al. EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring. Eur Heart J 2015; 36: 158-169.

90. Amy DockserMarcus C.W. Heart gadgets testprivacy-law limits. Wall St J. Available at: http://www.wsj.com/articles/SB10001424052970203937004578078820874744076.

91. Halperin D., Heydt-Benjamin T.S., Ransford B., Clark S.S., Defen B., Morgan W., Fu K., Kohno T., Maisel W.H. Pacemakers and implantable cardiac defibrillators: software radio attacks and zero-power defenses. security and privacy. In: Proceedings of the IEEE Symposium on Security and Privacy. 2008: 129-142.

92. Sanna T., Diener H.-C., Passman R.S., Di Lazzaro V., Bernstein R.A., Morillo C.A., et al. Cryptogenic stroke and underlying atrial fibrillation. New England Journal of Medicine 2014; 370(26): 2478-2486.